Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance - PubMed (original) (raw)

. 2018 Sep;46(9):3959-3969.

doi: 10.1177/0300060518782780. Epub 2018 Jul 3.

Peize Wang 1, Fei Guo 1, Xinmin Liu 1, Taiyang Luo 1, Yang Guan 1, Hui Chen 2, Zhanhong Wang 2, L Zhao 2, Xiaohai Ma 2, Qiang Lv 1, Yin Zhang 1, Junping Kang 1, Tong Liu 1, Xiaohui Liu 1, Jian-Zeng Dong 1, Rong Bai 1

Affiliations

Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance

Zichuan Zhang et al. J Int Med Res. 2018 Sep.

Abstract

Objective This study was performed to assess the prevalence of nonalcoholic fatty liver (NAFL) in patients with symptomatic congestive heart failure (CHF) and compare the clinical features with those of patients without NAFL. Methods In total, 102 patients with CHF were divided into NAFL and non-NAFL groups according to their hepatic ultrasonography findings. All patients underwent transthoracic echocardiography and cardiac magnetic resonance examination. Follow-up was performed for major cardiovascular events (MACE) and readmission due to heart failure at 1, 3, 6, and 12 months after the index hospitalization. Results NAFL was detected in 37 of 102 patients (36.27%). Compared with the non-NAFL group, patients with NAFL were younger, had a higher body mass index and left ventricular (LV) mass index, and had more severe fibrosis. MACE and readmission occurred in 15 patients in the NAFL group and 29 patients in the non-NAFL group, without a significant difference. Linear regression analysis revealed that after adjusting for confounders, NAFL was independently associated with the LV fibrosis size and the ratio of the LV fibrosis size to the LV mass index. Conclusions NAFL is present in more than one-third of patients with CHF and is associated with the severity of LV fibrosis.

Keywords: Heart failure; fibrosis; magnetic resonance; major cardiovascular events; nonalcoholic fatty liver disease; ultrasonography.

PubMed Disclaimer

References

    1. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7: 846–858. - PMC - PubMed
    1. Vanwagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 2015; 62: 773–783. - PMC - PubMed
    1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur J Heart Failure 2016; 18: 2129.
    1. Sîrbu O, Floria M, Dăscăliţa P, et al. Non-alcoholic fatty liver disease–From the cardiologist perspective. Anatolian Journal of Cardiology 2016; 16: 534–541. - PMC - PubMed
    1. Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006; 40: 949–955. PMID: 17063117. - PubMed

MeSH terms

LinkOut - more resources